Blind concept
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.

(Most gains, however, were quickly sold off.)

Autosomal Dominant Optic Atrophy (ADOA) ultimately leads to lesions and leakage of fluids within the eye that deteriorates such that most with the condition are legally blind by middle age.

After a review of the first batch of four-week data, the company has the green tick to continue. That would be normal in itself were it not for PYC’s +40% 1Y returns, putting it among a cohort of ASX biotech stocks currently having a fairly good run.

PYC’s main value proposition for ADOA treatments is that the condition has no known cure. PYC’s flagship drug is administered to the eye on the scale of micrograms – those doses will get bigger so long as trialling patient outcomes remain positive.

“PYC will now progress to dosing patients in cohort two of this trial with a view to establishing the safety/tolerability and initial efficacy profile of this drug candidate through the course of 2025,” the company wrote on Friday.

PYC last traded at $1.22.

Join the discussion: See what HotCopper users are saying about PYC Therapeutics and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.

PYC by the numbers
More From The Market Online
Imaging machine for the brain

Actinogen reports busy 6 months as development of Xanamem molecule ramps up

Actinogen Medical Ltd said it had pared back net losses in the 6 months to December…
Market Close Graphic

ASX Market Close: Choppy earning season continues; WTC pulls down tech

It was another tumultuous day for earnings reports as a basket of companies sunk into the…
Copper ore

Survey work suggests new zone for Locksley at Cu-Au project Tottenham

Locksley Resources Ltd has run a downhole electromagnetic survey across sections of its Tottenham copper project…
The Market Online Video

ASX Market Update: Financial bounces back as Oz bourse gains on lower opening | Feb 24, 2025

The Australian bourse made some gains on a low opening, as banking stocks led the gains…